Lipid Medication Effect Calculator

Statin, PCSK9i & Adjunct Therapy Projections

Medication Effect Tool
Baseline Values
Therapy Selection
10 mg daily (lookup-driven)
180 mg daily (if both BA+EZE, uses Nexlizet data)
Matched dataset row:
Projected LDL-C
Projected Non-HDL-C
Projected ApoB
Estimates assume moderate baseline LDL-C (130–160 mg/dL) and full adherence. Effects at 6–12 weeks.

For clinical and educational use only. Not intended to replace professional medical judgment.

FOR CLINICIANS

Want to know where your patient needs to get based on where they're starting from?

Treatment targets for ApoB, non-HDL, and LDL-C depend on your patient's baseline cardiometabolic risk. A Cardiometabolic Risk Assessment integrates LP-IR, Lp(a), metabolic syndrome severity, PREVENT measured ASCVD risk, and 30+ additional risk enhancing factors to establish that baseline — delivered to you in just 3–4 business days..

View a Sample Report

Also tracking metabolic syndrome severity? Use our free MSSS Calculator.

Limitations and Assumptions:

  1. Population Heterogeneity: Data derived primarily from clinical trial populations may not fully represent real-world responses.

  2. Baseline LDL-C Variability: Combination effects assume moderate baseline LDL-C levels (130-160 mg/dL).

  3. Adherence: Estimates assume perfect medication adherence.

  4. Time to Effect: Statin and ezetimibe effects at 6-8 weeks; PCSK9 inhibitors at 12 weeks; inclisiran at 6 months (after loading)

  5. Drug Interactions: No adjustment made for potential drug-drug interactions

  6. Genetic Factors: No stratification by genetic polymorphisms (e.g., PCSK9, SLCO1B1)

Note: This comprehensive table represents the best available evidence synthesized from clinical trials, meta-analyses, FDA-approved labeling, and expert guidelines. For triple combinations and some dual combinations with limited direct evidence, estimates are modeled based on established pharmacodynamic principles and known mechanisms of action. Clinical decision-making should account for individual patient characteristics, baseline lipid levels, cardiovascular risk, and treatment goals.